CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF...License Agreement • May 29th, 2020 • Forma Therapeutics Holdings, Inc., • Biological products, (no disgnostic substances) • New York
This [***] LICENSE AGREEMENT (this “Agreement”) is entered into and made effective as of December 28, 2018 (the “Effective Date”) by and among Forma Parent (solely for purposes of Articles 4, 5, 7 and 9) and Forma Inc. (as each such term is defined in Exhibit A), and Celgene Alpine Investment Company II, LLC, a Delaware limited liability company (“Celgene”). Forma Parent, Forma Inc. and Celgene are each referred to herein by name or as a “Party” or, collectively, as the “Parties.”
EMPLOYMENT AGREEMENTEmployment Agreement • May 29th, 2020 • Forma Therapeutics Holdings, Inc., • Biological products, (no disgnostic substances) • Massachusetts
THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into as of the 6th day of October, 2008 (the “Effective Date”), by and between STEVEN TREGAY (the “Employee”) and FORMA THERAPEUTICS, INC., a Delaware corporation duly organized under law and having a usual place of business at 790 Memorial Drive, Cambridge, MA 02139 (the “Company”).
CONFIDENTIAL October 31, 2019 (as revised February 25, 2020) Dr. Steven Tregay Re: Separation and Release Agreement Dear Steve:Release Agreement • May 29th, 2020 • Forma Therapeutics Holdings, Inc., • Biological products, (no disgnostic substances)
This letter constitutes the separation agreement (the “Agreement”) that FORMA Therapeutics, Inc. (the “Company”) is offering to you to aid in your employment transition. As you know, the Company has previously offered you (in June 2019 and in October 2019) prior separation agreements, which you declined to sign. We understand you have now decided to enter into a separation agreement consistent with your rights under your October 6, 2008 Employment Agreement with the Company, as amended (the “Employment Agreement”), and therefore offer this Agreement, which will superseded all prior separation agreements offered to you.
THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • May 29th, 2020 • Forma Therapeutics Holdings, Inc., • Biological products, (no disgnostic substances) • Delaware
THIS THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of December 18, 2019, by and among Forma Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), each of the investors listed on Exhibit A hereto, each of which (together with any transferee of Preferred Shares or Registrable Securities that agrees to be bound by and subject to the terms and conditions of this Agreement as an Investor hereunder in accordance with Section 6.1 hereto) is referred to in this Agreement as an “Investor.”
